Cargando…
Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience
Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in mos...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556530/ https://www.ncbi.nlm.nih.gov/pubmed/31239728 http://dx.doi.org/10.2147/IDR.S202346 |
_version_ | 1783425344072581120 |
---|---|
author | Hassan, Amro Metwaly Shawky, Muhammad Abd El-Gawad Mohammed, Ahmed Qasem Haridy, Mustafa Ahmed Eid, Khaled Abd-El-Azeem |
author_facet | Hassan, Amro Metwaly Shawky, Muhammad Abd El-Gawad Mohammed, Ahmed Qasem Haridy, Mustafa Ahmed Eid, Khaled Abd-El-Azeem |
author_sort | Hassan, Amro Metwaly |
collection | PubMed |
description | Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate. |
format | Online Article Text |
id | pubmed-6556530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65565302019-06-25 Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience Hassan, Amro Metwaly Shawky, Muhammad Abd El-Gawad Mohammed, Ahmed Qasem Haridy, Mustafa Ahmed Eid, Khaled Abd-El-Azeem Infect Drug Resist Original Research Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate. Dove 2019-06-05 /pmc/articles/PMC6556530/ /pubmed/31239728 http://dx.doi.org/10.2147/IDR.S202346 Text en © 2019 Hassan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hassan, Amro Metwaly Shawky, Muhammad Abd El-Gawad Mohammed, Ahmed Qasem Haridy, Mustafa Ahmed Eid, Khaled Abd-El-Azeem Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title | Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title_full | Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title_fullStr | Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title_full_unstemmed | Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title_short | Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience |
title_sort | simvastatin improves the eradication rate of helicobacter pylori: upper egypt experience |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556530/ https://www.ncbi.nlm.nih.gov/pubmed/31239728 http://dx.doi.org/10.2147/IDR.S202346 |
work_keys_str_mv | AT hassanamrometwaly simvastatinimprovestheeradicationrateofhelicobacterpyloriupperegyptexperience AT shawkymuhammadabdelgawad simvastatinimprovestheeradicationrateofhelicobacterpyloriupperegyptexperience AT mohammedahmedqasem simvastatinimprovestheeradicationrateofhelicobacterpyloriupperegyptexperience AT haridymustafaahmed simvastatinimprovestheeradicationrateofhelicobacterpyloriupperegyptexperience AT eidkhaledabdelazeem simvastatinimprovestheeradicationrateofhelicobacterpyloriupperegyptexperience |